Author

Danielle Henry

Jewish General HospitalORCID 0000-0001-8851-7968Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:GWAS / association mapping· 1

Frequent Co-Authors

Alejandro Álvarez-QuilóniD· 1 shared Ariya Shiwram· 1 shared Artur VelosoiD· 1 shared Branka VuleseviciD· 1 shared C. Gary MarshalliD· 1 shared Cathy Caron· 1 shared Celia M.T. GreenwoodiD· 1 shared Charlotte GuzmaniD· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alejandro Álvarez-QuilónORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintFeb 15, 2025

A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma

Isabel Soria‐Bretones, Matias Casás‐Selves, Elliot Goodfellow…·Michal Zimmermann

This study shows neuroblastoma cells are hypersensitive to PLK4 inhibitor RP-1664 due to dual mechanisms of centriole loss and amplification, leading to cell death.

5 citations

humanbulk RNA-seq

𝕏 PostBluesky

Genetic & Genomic MedicineNature MedicinePeer-reviewedFeb 25, 2021

A Neanderthal OAS1 Isoform Protects Against COVID-19 Susceptibility and Severity: Results from Mendelian Randomization and Case-Control Studies

Sirui Zhou, Guillaume Butler‐Laporte, Tomoko Nakanishi…·John Brent Richards

This study identifies OAS1 as a protective factor against COVID-19 severity and susceptibility using Mendelian randomization and case-control analyses.

273 citationstop 1%

humanproteomics

𝕏 PostBluesky